AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.GB2010051905 Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseasesSE2009050900 A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonistSE2009000264 Combination of (a) glucocorticoid receptor modulator and (b) a β2-agonist
It has completed a phase II clinical trial. See also Dagrocorat Fosdagrocorat Mapracorat
References
External links AZD-5423 - AdisInsight